BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/26/2024 1:28:46 PM | Browse: 215 | Download: 701
 |
Received |
|
2023-09-27 07:51 |
|
Peer-Review Started |
|
2023-09-27 07:53 |
|
First Decision by Editorial Office Director |
|
2023-12-04 19:48 |
|
Return for Revision |
|
2023-12-04 19:48 |
|
Revised |
|
2023-12-18 15:25 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2024-01-25 03:03 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2024-01-25 05:04 |
|
Articles in Press |
|
2024-01-25 05:04 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-02-20 00:53 |
|
Publish the Manuscript Online |
|
2024-02-26 13:28 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Hong-Xiao Wu, Xiao-Yan Ding, Ya-Wen Xu, Ming-Hua Yu, Xiao-Mi Li, Na Deng and Jing-Long Chen |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jing-Long Chen, Doctor, Chief Doctor, Cancer Center, Beijing Ditan Hospital, Capital Medical University, No. 8 Jingshun East Street, Chaoyang District, Beijing 100015, China. cjl6412@ccmu.edu.cn |
| Key Words |
Hepatocellular carcinoma; Transcatheter arterial chemoembolization; Lenvatinib; PD-1 inhibitor; Portal vein tumor thrombus |
| Core Tip |
Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) has a poor prognosis and treatment responses. Assessment of its survival has important clinical implications. Through our research, we discovered that a triplet regimen of PD-1 inhibitor/TACE/Lenvatinib was safe and well-tolerated as well as exhibited favorable efficacy over the TACE/Lenvatinib regimen for advanced-stage HCC comorbid with PVTT. |
| Publish Date |
2024-02-26 13:28 |
| Citation |
Wu HX, Ding XY, Xu YW, Yu MH, Li XM, Deng N, Chen JL. Transcatheter arterial chemoembolization combined with PD-1 inhibitors and Lenvatinib for hepatocellular carcinoma with portal vein tumor thrombus. World J Gastroenterol 2024; 30(8): 843-854 |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i8/843.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i8.843 |
© 2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
